Plus   Neg

Stock Alert: Enlivex Soars On Positive Results From Its Covid-19 Drug

Shares of clinical-stage immunotherapy company, Enlivex Therapeutics Ltd. (ENLV) are surging nearly 70% Thursday morning after the company reported positive top-line results from the study of its Covid-19 drug candidate, Allocetra.

The investigator-initiated study of Allocetra included five Covid-19 patients- three in severe condition and two in critical condition. All five patients had complete recovery from their respective condition and were released from the hospital, following administration of Allocetra, Enlivex said

There were no reported severe adverse events relating to the administration of Allocetra in the patients, and the therapy was well-tolerated, the company noted.

The company plans to start phase IIb study of Allocetra in the fourth quarter of 2020.

Enlivex stock is currently trading at $10.07. It has traded in the range of $3.59- $27.28 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Editors Pick
The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates. Retail sales are projected to grow at a potentially record rate during 2021, but the ongoing COVID-19 pandemic remains the biggest challenge for the year, according to the National Retail Federation. "There is no doubt the economy is positioned for growth in 2021, but how much growth comes down to a single non-economic force - the coronavirus," NRF Chief Economist Jack Kleinhenz said.
Follow RTT